TQ Therapeutics GmbH, a biotechnology company dedicated to advancing the field of cellular therapies through innovative technologies, today announced the acquisition of Juno Therapeutics GmbH (“Juno GmbH”), a cell therapy company, through a share purchase agreement. Juno GmbH is a German subsidiary of Juno Therapeutics, Inc., which is a wholly owned subsidiary of the global biopharmaceutical company, Bristol Myers Squibb. The financial terms of the agreement were not disclosed.

TQx is transforming the traditional production of cell therapies towards a decentralised, scalable, fast and highly automated cost-efficient platform. The acquisition of Juno GmbH will increase TQx’s capabilities, expanding access to intellectual property and license agreements that will support the development of the company’s potentially transformative cell processing platform.

“This acquisition presents an incredible opportunity for us to continue development of our breakthrough ultra-short extracorporeal cell and gene therapy approach to create treatments of the future,” said Dr. Christian Eckert, CEO of TQx. “This strategic transaction reinforces our commitment to making cell and gene therapy broadly accessible to address the medical needs of many patients.”